People: ZELTIQ Aesthetics Inc (ZLTQ.O)

Summary

Name	Age	Since	Current Position
Mark Foley		2012	President, Chief Executive Officer, Director
Patrick Williams	40	2012	Chief Financial Officer, Senior Vice President
Michael Genau	52	2012	President - North American Franchise
Sergio Garcia-Rodriguez	50	2012	Senior Vice President, General Counsel and Corporate Secretary
Richard Poinsett	60	2011	Senior Vice President - Operations
Dennis Jarvis	61	2011	Chief Marketing Officer
Kristine Tatsutani	44	2011	Vice President - Enhanced Clinical Outcomes, Chief Technology Officer
Mary Fisher		2012	Director
Jean George	54	2005	Independent Director
Kevin O'Boyle	56	2011	Independent Director
Bryan Roberts	45	2005	Independent Director
Andrew Schiff	46	2010	Independent Director

» Insider Trading

Biographies

Name	Description
Mark Foley	Mr. Mark J. Foley serves as President, Chief Executive Officer, Director of Zeltiq Aesthetics Inc. Mr. Foley has served on the ZELTIQ Board of Directors since 2009, and previously served as interim President and Chief Executive Officer of ZELTIQ since April 2012, and as Executive Chairman of the Board of Directors of ZELTIQ from July 2009 to May 2010. Mr. Foley currently serves as the President and Chief Executive Officer of ZELTIQ Aesthetics, and as a Managing Director of RWI Ventures. While at RWI Ventures, he has led investments in and served on the boards of companies such as BaroSense, Sonitus, and Voyage Medical. Additionally, Mr. Foley serves as Executive Chairman for Onpharma. Prior to joining RWI Ventures in May 2004, Mr. Foley spent 17 years in senior operating roles in both and start-up medical device companies, most recently founding and serving as Chief Executive Officer of Ventrica, Inc., which was acquired by Medtronic in 2004. Before Ventrica, Inc., Mr. Foley worked for several medical device companies, including Perclose (acquired by Abbott), Guidant, DVI (acquired by Eli Lilly), and U.S. Surgical (acquired by Tyco). Mr. Foley received his B.A. from the University of Notre Dame.
Patrick Williams	Mr. Patrick Williams is appointed as the Chief Financial Officer, Senior Vice President of ZELTIQ Aesthetics, Inc. He served as Vice President, Strategy and Investor Relations, of NuVasive, Inc., a publicly-traded medical device company focused on developing minimally disruptive surgical products and procedures for the spine, from February 2011 until November 2012, where he worked directly with the company’s CEO and senior management team to develop the company’s long term growth and operational strategy while ensuring alignment across the organization. Mr. Williams was Vice President, Financing and Investor relations at NuVasive from June 2007 until February 2011, in which capacity he was responsible for the day-to-day operations of the finance department including developing the worldwide budget and forecast, identifying profitability improvements, and predicting necessary infrastructure changes to support top-line growth and operating margins. He also had responsibility for managing all aspects of NuVasive’s investor relations efforts as well as government affairs duties. Prior to NuVasive, he was Director of Financial Planning and Analysis at Callaway Golf (NYSE: ELY), where he managed the day-to-day operations of the finance department including budgeting and forecasting, companywide operational analysis and financial reporting. Prior to Callaway, Mr. Williams held senior finance positions at Kyocera Wireless. He holds an MBA in Finance and Management from San Diego State University and a BA in Economics from University California at San Diego.
Michael Genau	Mr. Michael C. Genau serves as President - North American Franchise of Zeltiq Aesthetics Inc., since March 2012. Prior to joining ZELTIQ , Mr. Genau served as President of the global Active Healing Solutions business at Kinetic Concepts, Inc. from July 2009 to December 2011. Prior to that, Mr. Genau worked for GE Healthcare from January 2001 to June 2009 where he held executive and management positions for several key divisions within GE including: Global Diagnostic X-Ray and Mammography, Maternal Infant Care, Clinical Systems, GE Medical Systems Europe and Cardiology Systems. He also previously served as Executive Vice President and General Manager for Critikon Company, LLC, which was sold to GE Medical Systems. Earlier in his career, Mr. Genau held global sales, marketing, and product management positions for Johnson & Johnson. Mr. Genau earned a B.A. in international studies at the University of South Carolina – Columbia.
Sergio Garcia-Rodriguez	Mr. Sergio Garcia-Rodriguez serves as Senior Vice President, General Counsel and Corporate Secretary of Zeltiq Aesthetics Inc., since March 2012. Prior to joining ZELTIQ, Mr. Garcia was a partner at Reed Smith LLP and Fenwick & West LLP, July 2008 to March 2012 and October 2005 to July 2008, respectively, where he advised clients on corporate, transactional, and regulatory compliance matters including corporate governance, strategic transactions, mergers and acquisitions, public disclosure issues, and SEC reporting and compliance. He also served as outside general counsel to early-stage companies on intellectual property matters, strategic alliances, licensing and collaboration agreements, partnership agreements, financing, and litigation. Prior to that, Mr. Garcia played a key role as Vice President, Legal and General Counsel at PDL BioPharma Inc., where he acted as legal advisor to the executive management team and board of directors on a wide range of strategic and operational issues. Mr. Garcia earned a B.A. in international relations at Stanford University and J.D., Law at University of California, Berkeley – School of Law.
Richard Poinsett	Mr. Richard W. Poinsett is Senior Vice President - Operations of Zeltiq Aesthetics Inc., since July 2011. Prior to joining ZELTIQ, he served as Vice President of Reliability, Integrity and Supply Chain from June 2010 to July 2011. He also manages the execution of global expansion plans to accelerate growth in the aesthetic device market. Prior to joining ZELTIQ, Mr. Poinsett served as Vice President of Quality Assurance, Regulatory Affairs and Engineering at Greer Laboratories, Inc. from November 2004 to June 2010; Vice President, Development, Regulatory Affairs and Quality Assurance for In Sound Medical, Inc. from October 2003 to June 2004; and General Manager of REVA Medical, Inc. from September 2001 to December 2003. Prior to REVA Medical, Inc., he held several senior operations management positions at medical device companies. Mr. Poinsett brings over 20 years of senior management experience in operations, R&D, quality assurance, and regulatory affairs to ZELTIQ, primarily in the medical device sector. Mr. Poinsett holds an M.B.A. from Pepperdine University and a B.S. in electrical engineering from Purdue University.
Dennis Jarvis	Mr. Dennis J. Jarvis, Ph.D., is Chief Marketing Officer of Zeltiq Aesthetics Inc., since January 2011. Prior to joining ZELTIQ, Mr. Jarvis served as Vice President of Marketing at Ophthonix, Inc., a venture-backed vision correction company, from August 2003 to December 2010 and as Group Director of Marketing with VISTAKON, Johnson & Johnson Vision Care from June 1998 to December 2001. Prior to crossing over into the medical technology field, he held senior management positions focusing on marketing, sales, and market research with prominent consumer companies including The Gillette Company, where he was responsible for launching 15 new products, as well as Reebok, Ltd. and Spencer Gifts, a division of NBC-Universal. Mr. Jarvis began his career with Marsteller Inc., the advertising arm of global public relations and communications firm Burson-Marsteller. Mr. Jarvis earned his Ph.D. and Masters of Arts in Communications from Southern Illinois University and his B.S. from The College at Brockport, State University of New York. He also taught Marketing Management in the M.B.A program at Simmons College in Boston.
Kristine Tatsutani	Dr. Kristine N. Tatsutani, Ph.D., is Vice President - Enhanced Clinical Outcomes, Chief Technology Officer of Zeltiq Aesthetics Inc. She had previously served as Chief Technology Officer and Vice President of Clinical Affairs since May 2011. Dr. Tatsutani has 17 years of experience in the field of medical research and medical devices specifically focused in cryogenic applications in oncology, interventional cardiology, electrophysiology, and aesthetic medicine. Prior to joining ZELTIQ, Dr. Tatsutani served as Vice President, Clinical and Scientific Development at MyoScience, Inc., a company developing a cryogenic technology for another aesthetic application, from June 2008 to May 2011. Before that, she held scientific and clinical leadership positions at Boston Scientific from March 2005 to May 2008, and at CryoVascular Systems, Inc. from September 1998 to March 2005. Dr. Tatsutani earned her Ph.D. in Mechanical Engineering, specializing in cryobiology, as well as her Master of Science and Bachelor of Science in Mechanical Engineering at the University of California, Berkeley. She has multiple patents and scientific publications in the field of cryobiology and cryogenic medicine.
Mary Fisher	Ms. Mary M. Fisher has been appointed as the Director of Zeltiq Aesthetics Inc. Ms. Fisher joined SkinMedica as Chief Executive Officer, and as a member of the Board of Directors, in April 2008. Her previous experience includes more than 25 years in the pharmaceutical and biotechnology industries. Most recently, she was Chief Operating Officer of Acorda Therapeutics, a CNS company, with responsibility for corporate strategy and business development, financial planning, sales and marketing, and manufacturing. Previously, Ms. Fisher was Vice President, Strategic Healthcare and Commercial Operations for Cephalon, with responsibility for product planning and marketing, managed care sales, and manufacturing. Her earlier experience includes positions at Immunex and Boehringer Ingelheim. She is also a member of the Board of Neuroscience Nursing Foundation.
Jean George	Ms. Jean M. George is an Independent Director of Zeltiq Aesthetics Inc., since 2005. Ms. George is a General Partner at Advanced Technology Ventures. She joined the firm in 2002 and serves as the firm’s East Coast lead partner for healthcare investments. She brings more than 20 years of biopharmaceutical industry experience to the Board, including service at Genzyme Corporation from 1988 to 1998. At Genzyme, Ms. George held a variety of operational roles in marketing, product development, and business development, including Vice President of Global Sales and Marketing. She also worked as a Vice President and Founder of Genzyme’s Tissue Repair Division. In 1998, Ms. George joined the venture capital community and was appointed to lead BancBoston Ventures’ life sciences investments. She is currently a Director of Acceleron Pharmaceuticals, Calithera Biosciences, Hydra Biosciences, and Portola Pharmaceuticals. Ms. George was a Director of Hypnion, Inc. and Proteolix, Inc. She was named a member of the Scientific Advisory Board for the Massachusetts Life Sciences Center. She holds an M.B.A. degree from Simmons College Graduate School of Management and a B.S. degree from the University of Maine.
Kevin O'Boyle	Mr. Kevin C. O'Boyle is an Independent Director of Zeltiq Aesthetics Inc., since July 2011. Mr. O’Boyle serves as Senior Vice President and Chief Financial Officer at Advanced BioHealing, Inc. since December 2010. Previously, Mr. O’Boyle served as the Chief Financial Officer of NuVasive, Inc., a medical device company focused on the design, development, and marketing of products for the surgical treatment of spine disorders, from January 2003 to December 2009 and the Executive Vice President of NuVasive from December 2004 to December 2009. Prior to that time, Mr. O’Boyle served in various positions during his seven years with ChromaVision Medical Systems, Inc., a publicly traded medical device firm specializing in the oncology market, including as its Chief Financial Officer and Chief Operating Officer. Also, Mr. O’Boyle held various positions during his six years with Albert Fisher North America, Inc., a publicly traded international food company, before it was sold in 1996, including Chief Financial Officer and Senior Vice President of Operations. Mr. O’Boyle is currently a member of the Board of Directors of Tornier N.V., a publicly-held global orthopedics company, and Genmark Diagnostics, Inc., a publicly traded molecular diagnostics company. Mr. O’Boyle is a CPA and received a B.S. in Accounting from the Rochester Institute of Technology and completed the Executive Management Program at the University of California at Los Angeles, John E. Anderson Graduate Business School.
Bryan Roberts	Dr. Bryan E. Roberts, Ph.D., is Independent Director of Zeltiq Aesthetics Inc., since 2005. Dr. Roberts joined Venrock, a venture capital investment firm, in 1997, where he serves as Partner. From 1989 to 1992, Dr. Roberts worked in the corporate finance department of Kidder, Peabody & Co., a brokerage company. Dr. Roberts is currently Chairman of the Board at Ironwood Pharmaceuticals, a publicly traded pharmaceutical company that discovers, develops, and intends to commercialize innovative human medicines, and also serves on the board of directors of several private companies. He previously served on the board of directors of Athenahealth, Inc., XenoPort, Inc., and Sirna Therapeutics, Inc. He received a B.A. from Dartmouth College and a Ph.D. in chemistry and chemical biology from Harvard University.
Andrew Schiff	Dr. Andrew N. Schiff, M.D., is an Independent Director of Zeltiq Aesthetics Inc., since July 2010. Dr. Schiff joined Aisling Capital in September of 1999 and has served as a Managing Partner since 2002. Prior to joining Aisling Capital, Dr. Schiff practiced internal medicine at The New York Presbyterian Hospital where he maintains his position as a Clinical Assistant Professor of Medicine. Dr. Schiff currently serves as a director of ARMGO Pharma, Inc., Dynova Laboratories, Inc., Miramar Laboratories, Inc., Planet Technologies, Inc., SkinMedica, Inc., and TransEnterix, Inc. Previously, he served as a director of Adams Respiratory Therapeutics, Inc., ArgiNOx Pharmaceuticals, Inc., Barrier Therapeutics, Inc., Bioenvision, Inc., Cempra Pharmaceuticals, Inc., CardioKine, Inc., Myogen, Inc., and Sirion Therapeutics, Inc. Dr. Schiff received his M.D. from Cornell University Medical College, his M.B.A. from Columbia University, and his B.S. with honors in Neuroscience from Brown University.

Basic Compensation

Name	Fiscal Year Total
Mark Foley	--
Patrick Williams	--
Michael Genau	--
Sergio Garcia-Rodriguez	--
Richard Poinsett	309,928
Dennis Jarvis	--
Kristine Tatsutani	1,353,570
Mary Fisher	--
Jean George	--
Kevin O'Boyle	--
Bryan Roberts	--
Andrew Schiff	--

As Of 30 Dec 2011

Options Compensation

Name	Options	Value
Mark Foley	0	0
Patrick Williams	0	0
Michael Genau	0	0
Sergio Garcia-Rodriguez	0	0
Richard Poinsett	0	0
Dennis Jarvis	0	0
Kristine Tatsutani	0	0
Mary Fisher	0	0
Jean George	0	0
Kevin O'Boyle	0	0
Bryan Roberts	0	0
Andrew Schiff	0	0

Insider Trading

Name	Shares Traded	Price
GARCIA SERGIO	7,688	$5.00
SULLIVAN KEITH J	2,918	$4.38
SULLIVAN KEITH J	5,000	$4.69
SULLIVAN KEITH J	10,000	$4.67
TATSUTANI KRISTINE N	12,119	$4.61
SULLIVAN KEITH J	40,000	$0.00
TATSUTANI KRISTINE N	12,119	$2.83
TATSUTANI KRISTINE N	5,696	$2.83
TATSUTANI KRISTINE N	1,079	$4.60
TATSUTANI KRISTINE N	5,696	$4.60
GARCIA SERGIO	9,625	$3.61
TATSUTANI KRISTINE N	2,700	$4.68
TATSUTANI KRISTINE N	2,700	$2.83
TATSUTANI KRISTINE N	844	$3.62
LAMM CARL	563	$3.62
TATSUTANI KRISTINE N	3,520	$4.60
TATSUTANI KRISTINE N	3,520	$2.83
TATSUTANI KRISTINE N	7,343	$2.83
TATSUTANI KRISTINE N	7,343	$4.68
TATSUTANI KRISTINE N	4,008	$4.86
TATSUTANI KRISTINE N	4,008	$2.83
WILLIAMS PATRICK F	75,000	$0.00
LAMM CARL	15,000	$0.00
TATSUTANI KRISTINE N	25,000	$0.00
DEBENEDICTIS LEONARD C	65,000	$0.00

» Full list on Insider Trading

People: ZELTIQ Aesthetics Inc (ZLTQ.O)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: